Consolidation PD-(L)1 inhibitor after definitive chemoradiotherapy for unresectable stage III NSCLC: A systematic review and meta-analysis of randomized controlled trials

Dahar Saba; A Eftaiha; Alina Bhat

Consolidation PD-(L)1 inhibitor after definitive chemoradiotherapy for unresectable stage III NSCLC: A systematic review and meta-analysis of randomized controlled trials

Dahar Saba
, A Eftaiha
, Alina Bhat

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	44
Issue number	Supp 16
State	Published - May 21 2026

Cite this

@article{7993649e229849b0b0d16cfe37b3fe1f,

title = "Consolidation PD-(L)1 inhibitor after definitive chemoradiotherapy for unresectable stage III NSCLC: A systematic review and meta-analysis of randomized controlled trials",

author = "Dahar Saba and A Eftaiha and Alina Bhat",

year = "2026",

month = may,

day = "21",

language = "American English",

volume = "44",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

number = "Supp 16",

}

TY - JOUR

T1 - Consolidation PD-(L)1 inhibitor after definitive chemoradiotherapy for unresectable stage III NSCLC: A systematic review and meta-analysis of randomized controlled trials

AU - Saba, Dahar

AU - Eftaiha, A

AU - Bhat, Alina

PY - 2026/5/21

Y1 - 2026/5/21

M3 - Article

SN - 0732-183X

VL - 44

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - Supp 16

ER -